These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 37696462)

  • 1. Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy.
    Yu X; Zhai X; Wu J; Feng Q; Hu C; Zhu L; Zhou Q
    Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166881. PubMed ID: 37696462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer.
    Zhang Y; Yang Y; Chen Y; Lin W; Chen X; Liu J; Huang Y; Wang H; Teng L
    Front Immunol; 2022; 13():1060497. PubMed ID: 36505487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in advanced gastric cancer, is it the future?
    Coutzac C; Pernot S; Chaput N; Zaanan A
    Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
    Cui C; Yu B; Jiang Q; Li X; Shi K; Yang Z
    Clin Exp Pharmacol Physiol; 2019 Jan; 46(1):3-10. PubMed ID: 30161295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment.
    Parvez A; Choudhary F; Mudgal P; Khan R; Qureshi KA; Farooqi H; Aspatwar A
    Front Immunol; 2023; 14():1296341. PubMed ID: 38106415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
    Lin EM; Gong J; Klempner SJ; Chao J
    World J Gastroenterol; 2018 Jul; 24(25):2686-2697. PubMed ID: 29991874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
    Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
    Front Immunol; 2020; 11():1721. PubMed ID: 33072064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progression of immunotherapy in gastric cancer].
    Wei X; Xu R
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Feb; 19(2):225-32. PubMed ID: 26831889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
    Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
    Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies for gastric cancer targeting immune cells: Future directions.
    Zhao Y; Bai Y; Shen M; Li Y
    Front Immunol; 2022; 13():992762. PubMed ID: 36225938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research Advances of Immunotherapy of Exosome PD-L1 
in Non-small Cell Lung Cancer].
    Wang N; Song X
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.